PSC
Patient Square Capital Portfolio holdings
AUM
$467M
1-Year Est. Return
175.86%
This Fund
S&P 500
1 Year Est. Return
+175.86%
AUM
$467M
AUM Growth
+$93.3M
(+25%)
Holding
33
Top Buys
| 1 | +$22.7M | |
| 2 | +$14M | |
| 3 | +$8.99M | |
| 4 |
Cogent Biosciences
COGT
|
+$8.92M |
| 5 |
Terns Pharmaceuticals
TERN
|
+$7.4M |
Top Sells
| 1 | +$85.1M | |
| 2 | +$11.6M | |
| 3 | +$10.8M | |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$5.37M |
| 5 |
Liquidia Corp
LQDA
|
+$4.93M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$19.9B
| $177M | 37.93% |
8,166,047
-4,313,953
|
|
||
2
Insmed
INSM
$31B
| $46.5M | 9.95% |
267,000
-59,400
|
|
||
3
Mirum Pharmaceuticals
MIRM
$5.47B
| $23.6M | 5.05% |
298,682
+194,420
|
|
||
4
argenx
ARGX
$42.4B
| $21.9M | 4.68% |
26,000
+10,500
|
|
||
|
ONC
5
BeOne Medicines Ltd
ONC
$31.4B
| $21.1M | 4.51% |
+69,312
|
|
||
|
ABVX
6
Abivax
ABVX
$9.73B
| $17.5M | 3.75% |
130,000
-21,833
|
|
||
7
Pharvaris
PHVS
$1.7B
| $15.1M | 3.22% |
542,696
+197,315
|
|
||
8
EyePoint Inc
EYPT
$1.15B
| $14.3M | 3.05% |
780,000
-231,839
|
|
||
|
9
Terns Pharmaceuticals
TERN
$5.34B
| $12.9M | 2.77% |
+320,000
|
|
||
10
Celcuity
CELC
$5.23B
| $12M | 2.56% |
120,000
+20,000
|
|
||
|
11
Cogent Biosciences
COGT
$5.62B
| $11.3M | 2.41% |
+317,372
|
|
||
12
Kymera Therapeutics
KYMR
$6.5B
| $10.8M | 2.32% |
139,000
+46,408
|
|
||
|
13
Liquidia Corp
LQDA
$3.29B
| $7.83M | 1.68% |
227,000
-173,000
|
|
||
|
DBVT
14
DBV Technologies
DBVT
$1.08B
| $6.88M | 1.47% |
+359,050
|
|
||
15
Allogene Therapeutics
ALLO
$499M
| $6.8M | 1.46% |
4,963,756
+1,982,360
|
|
||
16
Dianthus Therapeutics
DNTH
$3.46B
| $6.18M | 1.32% |
150,000
+25,000
|
|
||
17
Xenon Pharmaceuticals
XENE
$5.26B
| $6.12M | 1.31% |
+136,500
|
|
||
18
Arcutis Biotherapeutics
ARQT
$2.84B
| $6.1M | 1.31% |
+210,000
|
|
||
19
Ocular Therapeutix
OCUL
$1.8B
| $5.95M | 1.27% |
490,000
-225,000
|
|
||
20
Disc Medicine
IRON
$2.26B
| $5.88M | 1.26% |
74,000
|
|
||
21
Avalo Therapeutics
AVTX
$263M
| $5.67M | 1.21% |
311,966
+211,966
|
|
||
22
Spyre Therapeutics
SYRE
$3.32B
| $4.91M | 1.05% |
+150,000
|
|
||
23
Enliven Therapeutics
ELVN
$1.8B
| $4.75M | 1.02% |
308,141
+57,303
|
|
||
24
Assembly Biosciences
ASMB
$435M
| $4.32M | 0.92% |
127,000
-8,182
|
|
||
25
Amylyx Pharmaceuticals
AMLX
$1.55B
| $4.23M | 0.91% |
350,000
+33,688
|
|